Growing community of inventors

Chatenay-Malabry, France

Emmanuel Heron

Average Co-Inventor Count = 5.00

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 1

Emmanuel HeronOlivier Hermine (2 patents)Emmanuel HeronMichel Paques (1 patent)Emmanuel HeronYves Colin (1 patent)Emmanuel HeronJean-Luc Wautier (1 patent)Emmanuel HeronYves Colin Aronovicz (1 patent)Emmanuel HeronJean-Francois Girmens (1 patent)Emmanuel HeronMarie-Paule Wautier (1 patent)Emmanuel HeronJean-François Girmens (0 patent)Emmanuel HeronEmmanuel Heron (2 patents)Olivier HermineOlivier Hermine (14 patents)Michel PaquesMichel Paques (4 patents)Yves ColinYves Colin (3 patents)Jean-Luc WautierJean-Luc Wautier (2 patents)Yves Colin AronoviczYves Colin Aronovicz (1 patent)Jean-Francois GirmensJean-Francois Girmens (1 patent)Marie-Paule WautierMarie-Paule Wautier (1 patent)Jean-François GirmensJean-François Girmens (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Institut National De La Sante Et De La Recherche Medicale (2 from 1,745 patents)

2. Assistance Publique-Hopitaux De Paris (2 from 321 patents)

3. Centre National De La Recherche Scientifique (1 from 5,094 patents)

4. Université Paris Descartes (1 from 132 patents)

5. Imagine Institut Des Maladies Genetiques Necker Enfants Malades (1 from 5 patents)

6. Universite Des Antilles Et De La Guyane (1 from 5 patents)

7. Université Paris Descartes—paris V (1 from 4 patents)

8. Universite Paris Diderot (Paris Vii) (1 from 4 patents)

9. Centre Hospitalier National D'ophtalmologie Quinze-Vingts (1 from 1 patent)

10. Institut National De La Transfusion Sanguinge (Ints) (1 from 1 patent)

11. Chn Ophtalmologie Quinze-Vingts (1 from 1 patent)


2 patents:

1. 10617658 - Use of hydroxycarbamide for preventing retinal nonperfusion

2. 9463217 - Methods and pharmaceutical compositions for treatment of retinal occlusion

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/11/2026
Loading…